# Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

> **NCT05432596** · PHASE2 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 250 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ATI-1777 2.0% w/w
- **DRUG:** ATI-1777 1.0% w/w
- **DRUG:** ATI-1777 0.5% w/w
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT05432596
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-11
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-11-14
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432596, "Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05432596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*